The Molecular Basis of Regio-Specificity in Fungal Polyketide Synthase

真菌聚酮合酶区域特异性的分子基础

• 批准号: 8840271
• 负责人: Michael D. Burkart
• 金额: $ 35.14万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-02-01 至 2018-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8840271
• 关键词: Active Sites; Address; Affect; Aflatoxins; Anabolism; Biological Assay; Biological Factors; Catalysis; Chemical Structure; Chemicals; Cholesterol; Cloning; Complex; Cross-Linking Reagents; Crosslinker; Crystallization; Cyclization; Engineering; Enzyme Interaction; Enzymes; Fungal Typing; Gene Cluster; Knowledge; Ligands; Lovastatin; Medical; Molds; Molecular; Multienzyme Complexes; Mutagenesis; Mutate; Mycotoxins; Outcome; Oxidoreductase; Pattern; Pharmaceutical Preparations; Protein Engineering; Proteins; Public Health; Research; Specificity; Structure; Structure-Activity Relationship; Substrate Specificity; Therapeutic; Toxin; Transacylase; base; cercosporin; combinatorial; crosslink; design; enzyme activity; genetic analysis; inhibitor/antagonist; mutant; polyketide synthase; protein protein interaction; protein structure; public health relevance; success

DESCRIPTION (provided by applicant): Polyketide natural products from filamentous fungi are highly diverse in both chemical structures and bioactivities, and they include the current top-selling drugs such as lovastatin (for cholesterol lowering), as well as potent toxins such as aflatoxin and cercosporin. Polyketides are biosynthesized by a multi- enzyme complex called polyketide synthase (PKS). There is a knowledge gap in correlating the PKS structures with protein-ligand interactions, enzyme catalysis, and substrate specificity. Such a knowledge gap has severely hampered our efforts to biosynthesize new polyketide-based therapeutics by PKS engineering. To address this issue, we aim to solve the crystal structures of non-reducing PKS (NRPKS), to correlate the product outcome with protein structures, and to biosynthesize new polyketides based on the structure-function studies. We will determine the sequence-structure-function relationship of the NRPKS complex and two NRPKS domains, the starter unit:ACP transacylase (SAT) and product template (PT). SAT and PT catalyze the polyketide chain initiation and cyclization, respectively, in a highly specific manner. We will pursue the following specific aims: Aim 1. Determine the molecular basis of cyclization specificity in NRPKS by crystal structures and mutagenesis different PTs that will synthesize new polyketides with altered cyclization patterns. Aim 2. Determine the molecular basis of starter unit specificity in NRPKS by crystal structures and mutagenesis different SATs followed by combinatorial biosynthesis to yield new polyketides with different starter units and cyclization patterns. Aim 3. Determine the importance of protein-protein interaction on product outcome using chemical crosslinkers by specific cross-linking probes that stabilize the complex and facilitate crystallization of multi-domain PKS complexes. We have already obtained diffracting crystals of crosslinked, multi-domain PKSs (a first in the PKS field), crystal structures of PTs, diffracting crystals of PTs and SATs conveying different specificities, validated crosslinkers, and optimized enzyme assays. Outcomes from the proposed research have two aspects of potential overall biomedical impact: (1) new polyketides with different cyclization patterns and starter units may be screened for new bioactivities, (2) the structures of PTs, SATs and NRPKS complex that biologically produces toxins can be applied to structure-based inhibitor design to identify new chemo-preventative agents against fungal toxin biosynthesis. Outcomes from the proposed research will have a high overall scientific impact, because it will not only determine how fungal PKSs specifically cyclize (AIM 1) and initiate (AIM 2) polyketide biosynthesis, but will also result in the first crystal structure of a PKS complex and elucidate how protein-protein interactions in the mega-synthase affects the product outcome (AIM 3).

描述(申请人提供)：丝状真菌的聚酮天然产物在化学结构和生物活性方面都具有高度的多样性，其中包括目前最畅销的药物，如洛伐他汀(用于降低胆固醇)，以及有效的毒素，如黄曲霉毒素和头孢菌素。聚酮化合物是由一种称为聚酮合成酶(PKS)的多酶复合体生物合成的。在PKS结构与蛋白质-配体相互作用、酶催化和底物专一性之间存在着知识鸿沟。这样的知识差距严重阻碍了我们通过PKS工程生物合成新的聚酮类药物的努力。为了解决这个问题，我们的目标是解决非还原PKS(NRPKS)的晶体结构，将产物与蛋白质结构联系起来，并在结构-功能研究的基础上生物合成新的聚酮。我们将确定NRPKS复合体和两个NRPKS结构域的序列-结构-功能关系，起始单元：ACP转酰酶(SAT)和产物模板(PT)。SAT和PT分别以高度特异性的方式催化聚酮链的引发和环化。我们将追求以下特定目标：目的1.通过晶体结构和诱变不同的PTT来确定NRPKS环化特异性的分子基础，这些PTT将合成具有改变环化模式的新的多酮。目的2.通过晶体结构和诱变不同的SAT，然后进行组合生物合成，获得具有不同起始单元和环化模式的新的聚酮，从而确定NRPKS起始单元专一性的分子基础。目的3.使用化学交联剂，通过特定的交联剂探针稳定复合体并促进多域PKS复合体的结晶，确定蛋白质-蛋白质相互作用对产物产物的重要性。我们已经获得了交联型多域PKS的衍射晶体(在PKS领域中是第一次)、PTS的晶体结构、携带不同特性的PTS和SAT的衍射晶体、验证的交联剂和优化的酶检测方法。拟议的研究成果在潜在的整体生物医学影响方面有两个方面：(1)具有不同环化模式和起始单元的新聚酮可能被筛选出新的生物活性；(2)生物产生毒素的PTS、SAT和NRPKS复合体的结构可以应用于基于结构的抑制剂设计，以确定新的针对真菌毒素生物合成的化学防御剂。拟议研究的结果将具有很高的整体科学影响，因为它不仅将确定真菌PKS如何特异性地环化(AIM 1)和启动(AIM 2)聚酮生物合成，而且还将导致PKS复合体的第一个晶体结构，并阐明巨合酶中的蛋白质-蛋白质相互作用如何影响产物结果(AIM 3)。

项目成果

A fine balancing act of type III polyketide synthase.

III 型聚酮合酶的良好平衡作用。

• DOI: 10.1016/j.chembiol.2004.09.001
• 发表时间: 2004
• 期刊: Chemistry & biology
• 作者: Tsai,Shiou-Chuan